GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (XMAD:GRF) » Definitions » Cyclically Adjusted PS Ratio

Grifols (XMAD:GRF) Cyclically Adjusted PS Ratio : 1.08 (As of Apr. 27, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Grifols Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Grifols's current share price is €8.386. Grifols's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was €7.74. Grifols's Cyclically Adjusted PS Ratio for today is 1.08.

The historical rank and industry rank for Grifols's Cyclically Adjusted PS Ratio or its related term are showing as below:

XMAD:GRF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.97   Med: 3.55   Max: 6.43
Current: 1.04

During the past years, Grifols's highest Cyclically Adjusted PS Ratio was 6.43. The lowest was 0.97. And the median was 3.55.

XMAD:GRF's Cyclically Adjusted PS Ratio is ranked better than
70.11% of 736 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs XMAD:GRF: 1.04

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Grifols's adjusted revenue per share data for the three months ended in Dec. 2023 was €2.606. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €7.74 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Grifols Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Grifols's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Cyclically Adjusted PS Ratio Chart

Grifols Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.91 4.18 - 1.51 2.00

Grifols Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 1.51 1.58 1.62 2.00

Competitive Comparison of Grifols's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Grifols's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Grifols's Cyclically Adjusted PS Ratio falls into.



Grifols Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Grifols's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=8.386/7.74
=1.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Grifols's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.606/121.2698*121.2698
=2.606

Current CPI (Dec. 2023) = 121.2698.

Grifols Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201306 1.025 100.994 1.231
201309 0.988 100.597 1.191
201312 0.999 101.306 1.196
201403 1.154 100.139 1.398
201406 1.174 101.081 1.408
201409 1.196 100.441 1.444
201412 1.335 100.251 1.615
201503 1.343 99.474 1.637
201506 1.417 101.138 1.699
201509 1.386 99.559 1.688
201512 1.532 100.268 1.853
201603 1.378 98.638 1.694
201606 1.426 100.333 1.724
201609 1.483 99.737 1.803
201612 1.608 101.842 1.915
201703 1.554 100.896 1.868
201706 1.651 101.848 1.966
201709 1.510 101.524 1.804
201712 1.563 102.975 1.841
201803 1.496 102.122 1.777
201806 1.625 104.165 1.892
201809 1.685 103.818 1.968
201812 1.740 104.193 2.025
201903 1.719 103.488 2.014
201906 1.836 104.612 2.128
201909 1.921 103.905 2.242
201912 1.967 105.015 2.271
202003 1.890 103.469 2.215
202006 2.172 104.254 2.526
202009 1.967 103.521 2.304
202012 1.898 104.456 2.204
202103 1.734 104.857 2.005
202106 1.975 107.102 2.236
202112 0.000 111.298 0.000
202206 2.273 118.044 2.335
202209 2.270 117.221 2.348
202212 2.525 117.650 2.603
202306 2.452 120.278 2.472
202309 2.352 121.343 2.351
202312 2.606 121.270 2.606

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Grifols  (XMAD:GRF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Grifols Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Grifols's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols (XMAD:GRF) Business Description

Industry
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.